top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

BeiGene finalizes a $1.3B Agreement with Ensem for the CDK2 Inhibitor

  • Nov 22, 2023
  • 1 min read

Cambridge, MA, November 21, 2023 (MSN) -- BeiGene secures global licensing for Ensem Therapeutics' oral cyclin-dependent kinase-2 (CDK2) inhibitor aimed at breast cancer treatment. The deal involves an undisclosed upfront payment to Ensem, with potential milestone payments totaling up to $1.33 billion, along with tiered royalties.


Read full article here.

 
 
 

Recent Posts

See All
Qlaris Bio Appoints Fred Guerard as CEO

Dedham, MA, March 1, 2026 (Business Wire) -- Qlaris Bio has appointed Fred Guerard, Pharm.D., as president and chief executive officer, effective March 1, 2026, and he will also join the company’s b

 
 
 

Comments


Life Science Headlines
bottom of page